ReviewFrontiers in oncology2021
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies.Human vaccines & immunotherapeutics · 2026Review
- Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.Clinical and translational gastroenterology · 2026Review
- Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology.Frontiers in immunology · 2026Review
- Observational
- Cellular characteristics of the immune microenvironment of colorectal cancer and progress in immunotherapy research.Annals of medicine · 2025Review
- Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions.Frontiers in medicine · 2025Review
- Article
- The characteristics of intratumoral microbial community reflect the development of lung adenocarcinoma.Frontiers in microbiology · 2024Article
- The Comparison of Serum Exosome Protein Profile in Diagnosis of NSCLC Patients.International journal of molecular sciences · 2023Article
- Article
- Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer.Chronic diseases and translational medicine · 2022Review
- Review
- Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel.Frontiers in oncology · 2022Article
- Circulating Tumor Cell Identification Based on Deep Learning.Frontiers in oncology · 2022Article
- A Machine Learning Method to Trace Cancer Primary Lesion Using Microarray-Based Gene Expression Data.Frontiers in oncology · 2022Article
- Predictive Biomarkers in Thyroid Cancer.Frontiers in oncology · 2022Review
- Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning.Frontiers in oncology · 2022Article
- Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning.Frontiers in oncology · 2022Article
- Lung Cancer Stage Prediction Using Multi-Omics Data.Computational and mathematical methods in medicine · 2022Article
- Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is one of the most prevalent causes of cancer-related death worldwide. Recently, there are many important medical advancements on NSCLC, such as therapies based on tyrosine kinase inhibitors and immune checkpoint inhibitors. Most of these therapies require tumor molecular testing for selecting patients who would benefit most from them. As invasive biopsy is highly risky, NSCLC molecular testing based on liquid biopsy has received more and more attention recently.
objectiveWe aimed to introduce liquid biopsy and its potential clinical applications in NSCLC patients, including cancer diagnosis, treatment plan prioritization, minimal residual disease detection, and dynamic monitoring on the response to cancer treatment.
methodWe reviewed recent studies on circulating tumor DNA (ctDNA) testing, which is a minimally invasive approach to identify the presence of tumor-related mutations. In addition, we evaluated potential clinical applications of ctDNA as blood biomarkers for advanced NSCLC patients.
resultsMost studies have indicated that ctDNA testing is critical in diagnosing NSCLC, predicting clinical outcomes, monitoring response to targeted therapies and immunotherapies, and detecting cancer recurrence. Moreover, the changes of ctDNA levels are associated with tumor mutation burden and cancer progression.
conclusionThe ctDNA testing is promising in guiding the therapies on NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.